Clinical Features of Anti-Synthetase Syndrome Associated with Prognosis in Patients with Dermatomyositis and Polymyositis

被引:7
作者
Ahn, Sung Soo [1 ]
Park, Yong-Beom [2 ,3 ]
Lee, Sang-Won [2 ,3 ]
机构
[1] Yonsei Univ, Yongin Severance Hosp, Coll Med, Dept Internal Med, Yongin 16995, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul 03722, South Korea
[3] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul 03722, South Korea
关键词
dermatomyositis; polymyositis; mortality; fever; anti-synthetase syndrome; clinical features; INTERSTITIAL LUNG-DISEASE; INFLAMMATORY MYOPATHIES; ANTISYNTHETASE SYNDROME; SHORT-TERM; MORTALITY; CYTOKINES; MACROPHAGE;
D O I
10.3390/jcm11072052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We evaluated whether the clinical features of anti-synthetase syndrome (ASA)-myositis, fever, arthritis, mechanic's hand, Raynaud's phenomenon and interstitial lung disease-are relevant to prognosis in patients with dermatomyositis/polymyositis (DM/PM). A retrospective analysis was performed to identify patients diagnosed with DM/PM according to Bohan and Peter criteria. Clinical information, laboratory data and the presence of ASA clinical features at disease diagnosis were searched, and the outcomes of all-cause mortality, intensive care unit admission and disease remission at 1 year were assessed. Among the 86 patients included, fever (36.0%) and interstitial lung disease (26.7%) were the most common ASA clinical features. During the follow-up, 12 patients experienced death, and 7 of the 12 deaths (58.3%) occurred within 3 months of DM/PM diagnosis. Mortality was more frequently observed in those presenting with fever than in those without (25.8% versus 7.3%, p = 0.024). Multivariable Cox proportional analysis revealed that male sex (hazard ratio [HR] 5.53, 95% confidence interval [CI] 1.65, 18.49, p < 0.01) and fever (HR 4.20, 95% CI 1.26, 14.01, p = 0.02) independently predicted mortality. The clinical impact of fever was consistent in both sexes. Fever could be a warning signal heralding the poor outcome of mortality in patients with DM/PM, especially in early disease phases.
引用
收藏
页数:11
相关论文
共 31 条
[1]   Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients [J].
Aggarwal, Rohit ;
Cassidy, Elaine ;
Fertig, Noreen ;
Koontz, Diane Carol ;
Lucas, Mary ;
Ascherman, Dana P. ;
Oddis, Chester V. .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :227-232
[2]   In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome [J].
Ahn, Sung Soo ;
Yoo, Byung-Woo ;
Jung, Seung Min ;
Lee, Sang -Won ;
Park, Yong-Beom ;
Song, Jason Jungsik .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) :216-221
[3]   Prognosis and mortality of polymyositis and dermatomyositis patients [J].
Airio, A ;
Kautiainen, H ;
Hakala, M .
CLINICAL RHEUMATOLOGY, 2006, 25 (02) :234-239
[4]   POLYMYOSITIS AND DERMATOMYOSITIS .2. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) :403-407
[5]   POLYMYOSITIS AND DERMATOMYOSITIS .1. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) :344-347
[6]   Long-term outcome in polymyositis and dermatomyositis [J].
Bronner, I. M. ;
van der Meulen, M. F. G. ;
de Visser, M. ;
Kalmijn, S. ;
van Venrooij, W. J. ;
Voskuyl, A. E. ;
Dinant, H. J. ;
Linssen, W. H. J. P. ;
Wokke, J. H. J. ;
Hoogendijk, J. E. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (11) :1456-1461
[7]   Antisynthetase syndrome: Not just an inflammatory myopathy [J].
Chatterjee, Soumya ;
Prayson, Richard ;
Farver, Carol .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2013, 80 (10) :655-666
[8]   Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies What Progress Has Been Made in the Past 35 Years? [J].
Connors, Geoffrey R. ;
Christopher-Stine, Lisa ;
Oddis, Chester V. ;
Danoff, Sonye K. .
CHEST, 2010, 138 (06) :1464-1474
[9]   Cytokines and fever [J].
Conti, B ;
Tabarean, I ;
Andrei, C ;
Bartfai, T .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :1433-1449
[10]  
Cook RJ, 2000, J RHEUMATOL, V27, P1892